直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

The Seventh Amendment Does Not Bar Pre-Verdict Supplemental Damages

March 9, 2021

Authored and Edited by Shannon M. Patrick; Kara A. Specht; Elizabeth D. Ferrill

In Bayer Healthcare LLC v. Baxalta Inc., No. 19-2418 (Fed. Cir. Mar. 1, 2021), the Federal Circuit reviewed many issues on appeal, including Baxalta’s Seventh Amendment challenge.

Baxalta argued that the district court violated the company’s Seventh Amendment right to a jury trial by awarding Bayer pre-verdict supplemental damages. The jury calculated damages between June 14, 2016 and November 30, 2018. The district court then awarded Bayer pre-verdict supplemental damages for the period between December 1, 2018 and the date the judgment was entered, February 8, 2019.

The Federal Circuit upheld the pre-verdict supplemental damages award. Although the Court noted that an additur would violate the Seventh Amendment, it found that the district court’s award was a proper damages award under 35 U.S.C. § 284, which gives the district court the ability to assess damages for the claimant that were not found by the jury. In awarding damages, the district court merely applied “the jury’s royalty rate to the undisputed actual infringing sales base” to calculate the damages. Slip op. at 32. Therefore, the district court’s pre-verdict damages award did not constitute “an impermissible additur or an otherwise ‘bald addition of something which in no sense can be said to be included in the verdict.’” Id. at 33.

 

Tags

damages

For more information

  • Bayer Healthcare LLC v. Baxalta Inc.

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Atlanta, GA

Washington, DC

Contacts

Shannon M. Patrick
Associate
Atlanta, GA
+1 404 653 6558
Email
Kara A. Specht
Partner
Atlanta, GA
+1 404 653 6481
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Charitable

TopGolf for the Troops 2026

June 11, 2026

Ashburn

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP